Skip to main content

Advertisement

Log in

Adrenal Castleman’s disease

  • Letter to the Editor
  • Published:
Annals of Hematology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2

References

  1. Keller AR, Hochholzer L, Castleman B (1972) Hyaline-vascular and plasma-cell types of giant lymph node hyperplasia of the mediastinum and other locations. Cancer 29:670–683

    Article  PubMed  CAS  Google Scholar 

  2. Bowne WB, Lewis JJ, Filippa DA, Niesvizky R, Brooks AD, Burt ME, Brennan MF (1999) The management of unicentric and multicentric Castleman’s disease: a report of 16 cases and a review of the literature. Cancer 85:706–717

    Article  PubMed  CAS  Google Scholar 

  3. Debatin JF, Spritzer CE, Dunnick NR (1991) Castleman disease of the adrenal gland: MR imaging features. AJR Am J Roentgenol 157:781–783

    PubMed  CAS  Google Scholar 

  4. Gupta NP, Ansari MS, Chopra P, Dinda AK (2002) Castleman’s disease masquerading as an adrenal tumor. J Urol 168:2524

    Article  PubMed  CAS  Google Scholar 

  5. Chen JH, Yu CY, Pai CY, Chan DC, Chen CJ, Yu JC, Liu YC (2005) Castleman’s disease in the left upper retroperitoneal space mimicking an adrenal neoplasm: report of a case and literature review. Jpn J Clin Oncol 35:353–356

    Article  PubMed  Google Scholar 

  6. Leger-Ravet MB, Peuchmaur M, Devergne O, Audouin J, Raphael M, Van Damme J, Galanaud P, Diebold J, Emilie D (1991) Interleukin-6 gene expression in Castleman’s disease. Blood 78:2923–2930

    PubMed  CAS  Google Scholar 

  7. Papanicolaou DA, Wilder RL, Manolagas SC, Chrousos GP (1998) The pathophysiologic roles of interleukin-6 in human disease. Ann Intern Med 128:127–137

    PubMed  CAS  Google Scholar 

  8. Mastorakos G, Chrousos GP, Weber JS (1993) Recombinant interleukin-6 activates the hypothalamic-pituitary-adrenal axis in humans. J Clin Endocrinol Metab 77:1690–1694

    Article  PubMed  CAS  Google Scholar 

  9. Franchimont N, Wertz S, Malaise M (2005) Interleukin-6: an osteotropic factor influencing bone formation? Bone 37:601–606

    Article  PubMed  CAS  Google Scholar 

  10. Erices A, Conget P, Rojas C, Minguell JJ (2002) Gp130 activation by soluble interleukin-6 receptor/interleukin-6 enhances osteoblastic differentiation of human bone marrow-derived mesenchymal stem cells. Exp Cell Res 280:24–32

    Article  PubMed  CAS  Google Scholar 

  11. Taguchi Y, Yamamoto M, Yamate T, Lin SC, Mocharla H, DeTogni P, Nakayama N, Boyce BF, Abe E, Manolagas SC (1998) Interleukin-6-type cytokines stimulate mesenchymal progenitor differentiation toward the osteoblastic lineage. Proc Assoc Am Physicians 110:559–574

    PubMed  CAS  Google Scholar 

  12. Müssig K, Gallwitz B, Machicao F, Horger M, Häring HU, Kaiserling E (2006) Paraadrenal Castleman disease presenting with adrenal hyperandrogenism. J Endocrinol Investig 29:172–176

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Karsten Müssig.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Müssig, K., Horger, M. & Wehrmann, M. Adrenal Castleman’s disease. Ann Hematol 86, 63–65 (2007). https://doi.org/10.1007/s00277-006-0200-7

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00277-006-0200-7

Keywords

Navigation